The inducible cyclic AMP (cAMP) early repressor (ICER) and cAMP response element-binding protein (CREB) are transcriptional regulators of the cAMP-mediated signaling pathway. CREB has been demonstrated to be upregulated in the majority of childhood leukemias contributing to disease progression, whereas ICER, its endogenous repressor, was found to be downregulated. Our research focus has been the function of restored ICER expression. ICER exogenously expressed in cell lines decreases CREB protein level and induces a lowered clonogenic potential in vitro. It decreases the ability of HL60 to invade the extramedullary sites and to promote bone marrow angiogenesis in nonobese diabetic-severe combined immunodeficient mice, demonstrating its potential effects on tumor progression. ICER represses the majority of 96 target genes upregulated by CREB. It binds CRE promoters and controls gene expression restoring the normal regulation of major cellular pathways. ICER is subjected to degradation through a constitutively active form of the extracellular signal-regulated protein kinase, which drives it to the proteasome. We propose that ICER is downregulated in HL60 to preserve CREB overexpression, which disrupts normal myelopoiesis and promotes blast proliferation. These findings define the function of ICER as a tumor suppressor in leukemia. Unbalanced CREB/ICER expression needs to be considered a pathogenetic feature in leukemogenesis. The molecular characterization of this pathway could be useful for novel therapeutic strategies.
Introduction
The inducible cyclic AMP (cAMP) early repressor (ICER) is a transcriptional factor that derives from an alternative promoter activation of the cAMP response element (CRE) modulator (CREM) gene. ICER is the unique CREM isoform that lacks the transactivation domain and conserves the DNA-binding domain; 1 it recognizes the CRE consensus region, which is present in a great number of promoter genes. It homodimerizes or heterodimerizes with the CRE-binding protein (CREB) or with CREM modulators mediating a final cAMP responsive genes repression, principally counteracting CREB activity. ICER expression is a transient phenomenon: it competes with CREB by binding and repressing CRE sequences that are present in its own promoter. This negative feedback control of ICER transcription is physiologically important for correct cAMPdependent gene expression in different tissues. 2 ICER activity is determined by its intracellular levels rather than by posttranslational modification, as it lacks the phosphorylation domain (P-box) typical of its CREB/CREM family member proteins. ICER expression depends on CREB/ICER transcriptional activity and its protein degradation rate. 3 CREB is a nuclear protein that regulates gene expression principally through activation of cAMP-dependent cell signal transduction pathways. CREB activity modulation was found to be a result of protein kinase A-dependent phosphorylation of CREB at Serine 133. This modification enhances the transactivation potential of CREB promoting the recruitment of several coactivators. 4, 5 It has been recently demonstrated that aberrant CREB expression in acute leukemia promotes abnormal proliferation, cell cycle progression and cell survival. 6 The inducible cyclic AMP (cAMP) early repressor has been demonstrated to influence cell growth in neuroendocrine tissue, cardiac myocytes and the liver. [7] [8] [9] Recently, it has been proposed as a tumor suppressor gene in prostate and pituitary cancers. 10, 11 We previously documented that ICER was downregulated at diagnosis of acute leukemia in a cohort of pediatric patients, whereas CREB protein was found to be overexpressed. On the contrary, the higher ICER expression was found in healthy bone marrow (BM) and during remission phases of leukemia therapy, whereas CREB expression was found to be significantly decreased. 12, 13 It is still unclear how the interplay of CREB and ICER affects gene expression and, consequently, cell proliferation and survival in leukemia. Considering that CREB-sustained expression in leukemia can cause an upregulation of a number of genes involved in different aspects of cell life and that ICERlowered expression does not allow physiological CREB-dependent gene repression, we considered elucidating CREB/ICER balanced expression and regulation as a crucial event in leukemogenesis. We aimed to study the leukemic phenotype after restoring ICER expression in HeLa and HL60 cells that normally do not express it. The second purpose of this study has been to establish how ICER acts on tumor cells and to explicate the mechanism that leads to ICER downregulation in leukemia.
Results provide evidence that the period of enhanced expression of ICER corresponds to the lowest level of CREB expression and to a significant modification of cell proliferation and survival in vivo. Expression analysis in vitro reveals that ICER significantly represses specific CREB target genes. We described ICER degradation by proteasome pathway as one of the possible causes of its lowered expression found in leukemia.
Materials and methods

Cell culture and transfection
HeLa and leukemia cell lines (HL60, FLG, NB4, 697, Jurkat, RS4;11) were obtained from the American Type Culture Collection and were cultured in Dulbecco's modified Eagle's medium or RPMI (Invitrogen-Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Invitrogen-Gibco). HeLa cells were grown on glass coverslips using Dulbecco's modified Eagle's medium (Invitrogen-Gibco) supplemented with 10% fetal bovine serum (Invitrogen-Gibco) until 70% confluent and were transiently transfected with 0.4 mg of pEGFPD-N1_FLAG-ICERg combined with 10 ml of Efectene (Qiagen, Hilden, Germany) according to the manufacturer's guidelines. After 24 and 48 h, cells were stained with anti-FLAG antibody and visualized by confocal microscopy. The empty vector (pEGFPD-N1) was used as negative control. HL60 was grown in suspension diluted at 500 Â 10 6 /ml, and after 24 h was transiently transfected with 1.5 mg of pEGFPD-N1_FLAG-ICERg combined with 100 ml of Solution V (Amaxa Biosystems, Koln, Germany) using Nucleofector (Amaxa Biosystems), according to the manufacturer's guidelines. After 24 and 48 h, cells were stained with anti-FLAG antibody to visualize ICER nuclear expression by confocal microscopy. Cells were also used for molecular analyses. A quantity of 1.5 mg of pEGFPD-N1 were transfected and used as negative control. To obtain a stable clone for ICER, 48 h after transfection, cells were cultured in Dulbecco's modified Eagle's medium supplemented with 1.2 mg/ml G418 for 3 weeks. Single cells were sorted and seeded in 96-well plate. Clones were expanded and screened for ICER expression by western blotting (WB). All analyses discussed above were performed in two independent stable clones and within seven scrambled stable clones all of which provided the same results. We indicated HL60 þ ICER cell line in those results obtained with ICER stable expression in text and figures. We considered stably empty vector (EV)-transfected cell line, defined as HL60 þ EV, as control.
Plasmid constructs and cloning
The human ICERg mRNA was amplified from HL60 cDNA using primers (PF1-5 0 ATGGCTGTAACTGGAGATGAAACAG3 0 ) and (PR1-CAAGGTCCAAGTCAAAGACAGTTACTCT), cloned in the pCR2.1TOPO vector (Invitrogen-Gibco), sequenced and compared with the deposited sequence (GenBank AF069065). ICERg was amplified from the cloned pCR2.1TOPO-ICERg plasmid, using the T7 primer and a reverse primer that contained the recognition sequence for NotI and also the sequence for the FLAG epitope (Sigma-Aldrich, St Louis, MO, USA). The PCR product was digested with NotI and EcoRI, and cloned into the pEGFPN1vector (Clontech, Otsu, Japan), which was excised of GFP (pEGFPD-N1) and digested with NotI and EcoRI (pEGFPD-N1_FLAG-ICERg). The empty vector was created from pEGFPN1 digested with EcoRI and NotI. Next, the EV was treated with Klenow enzyme to fill in overhangs and was self-ligated (pEGFPD-N1_EV). Clones were sequenced with suitable vector primers to confirm the correctness of the reading frame of the fusion gene.
The reporter vector (4XCREpGL3/LUC) was constructed using Luciferase gene (LUC) (Promega, Hamburg, Germany) as described before.
14 All transfections were performed with a second reporter, Renilla (REN) gene, as internal control vector for normalization (phRL-TK, Promega). The plasmids were prepared for transfection experiments using the maxiprep endonuclease-free kit (Qiagen).
Soft agar colony assay
A total of 2.5 Â 10 3 cells of HL60 þ ICER and HL60 þ EV cell lines were used to test the colony-forming cells. Cells were plated onto 2-well in a methylcellulose semisolid medium not supplemented with nutrients or cytokines (StemCell Technologies, Vancouver, BC, Canada) and incubated at 37 1C. The colonies were observed everyday and counted at day 12. Colony evaluation and enumeration was done in situ by light microscopy after 3-(4,55-dimethylthiazol-2-yl)-2,5diphenyltetrazo-lium incorporation.
In vivo assay
We used sex-and age-matched nonobese diabetic-severe combined immunodeficient mice. Mice received 250 cGy of total body irradiation up to 24 h before inoculation of 5 Â 10 6 of stable HL60 þ EV or HL60 þ ICER cells per mouse. Animals were killed after 3 weeks and the BM from flushing femurs, peripheral blood (PB) and internal organs were collected for histological and immunophenotypic analyses to determine the presence of invading leukemia cells. Leukemia engraftment was monitored in BM and PB by flow cytometric measuring of the amount of positive human-CD45 and murine-CD45 cells. Sections of BM and spleen were processed for histological examination using antihuman major histocompatibility complex class I antibody to evaluate tumor dissemination. To determine BM angiogenesis, BM sections were stained with anti-CD34 antibody, and vascular morphometric parameters were calculated as described previously. 15 The persistence of ICER expression during in vivo experiments was checked in stable transfectants in vitro.
Transfection and luciferase assay
A mixture of 0.3 mg of 4XCREpGL3/LUC, 0.3 mg of pEGFPD-N1_FLAG-ICERg or 0.3 mg of pEGFPD-N1_EV together with 0.1 mg of phRL-TK as internal control were used to transfect HeLa. A mixture of 0.75 mg of 4XCREpGL3/LUC, 0.75 mg of pEGFPD-N1_FLAG-ICERg or 0.75 mg of pEGFPD-N1_EV together with 0.24 mg of phRL-TK as internal control were used to transfect HL60. After 24 and 48 h, proteins were extracted and LUC activity was determined following the manufacturer's instructions (Promega). Luminescence was measured using a Luminescence counter (Perkin Elmer, Montreal, Canada). Results were normalized to Renilla activity, compensating for variation in transfection efficiency. Three parallels were used in all transfections and all experiments were performed in triplicate.
In vitro transcription
Single assay (Applied Biosystems, Foster City, CA, USA) was used to test HIF1a and vascular endothelial growth factor (VEGF) expression for their function in angiogenesis. A lowdensity array based on an Applied Biosystems 7900HT Micro Fluidic Card where probe and primer sets were factory-loaded into 384-well plate was then evaluated for wide gene expression analyses. 16, 17 A total of 96 genes, cited in the CREB database (http://natural.salk.edu/CREB/) for the high predictive value to contain CRE consensus sequence in their promoter, were chosen. We mixed 2 ml of single-stranded cDNA (equivalent to 100 ng of total RNA) with 48 ml of nuclease-free water and 50 ml of TaqMan Universal PCR Master Mix (Applied Biosystems). After we loaded 100 ml of the sample-specific PCR mixture into each sample port, the cards were centrifuged. Cards were analyzed on ABI PRISM 7900HT Sequence detection system and evaluated with the RQ Manager Software for automated data analysis (Applied Biosystems). Experiments were carried out in duplicate and were analyzed together as one relative quantity (RQ) study. Expression values for target genes were normalized to the concentration of GAPDH, which showed the least variation among reference genes in our cell model. Gene expression values were calculated on the basis of the comparative threshold cycle (C t ) method, where each RNA sample was calibrated to values obtained by the transient or stable transfection with empty vector. The Micro Fluidic Cards detect a fold difference in gene expression at a 99% confidence level.
Chromatin immunoprecipitation assay
HL60 þ ICER and HL60 þ EV cell lines were processed for chromatin immunoprecipitation assay (Upstate Cell Signaling Solutions, VA, USA) following the manufacturer's instructions. Other reagents required were purchased from the same source. A total of 1 Â 10 6 cells were lysed and sonicated (Fischer Scientific Model 300 Ultrasonic Dismembrator) three times for 10 s pulses at 40 power over ice. The immunoprecipitation was performed overnight at 4 1C with rotation by using an antibody of interest (1:50) and without antibody selection, as negative control. DNA was recovered and used to perform PCR with primers selected from gene promoter sequence (see Supplementary Table 1S for primer sequences). Amplified PCR products were resolved by 2.0% of agarose gel electrophoresis and visualized by ethidium. The difference in DNA promoters immunoprecipitated by phosphoCREB (P-CREB) in stable HL60 þ EV cell line was compared with that of HL60 þ ICER cell line and was calculated by RQ-PCR. It was performed using the 7900HT technology (Applied Biosystems) and the SYBR Green method for amplification and detection (InvitrogenGibco) (see Supplementary Table 1S primer sequences) . Expression values were calculated on the basis of the comparative threshold cycle (C t ) method. 18 Western blot 20 mg from total protein fraction (Buffer-Biosource by InvitrogenGibco) obtained from HeLa and HL60 transiently transfected cells, as well as for stable HL60 þ ICER and HL60 þ EV cell lines were used to perform protein analyses. Protein concentration was determined using the BCA method (Pierce, Rockford, IL, USA). Samples were subjected to 10-12% SDS-polyacrylamide gel electrophoresis and transferred to 0.2 mm polyvinylidene difluoride membranes (GE-Healthcare, IL, USA) for immunodetection with a series of antibodies followed by horseradish peroxidase-conjugated goat anti-rabbit or mouse IgG (Upstate Biotechnology, Lake Placid, NY, USA). Antibodies used included anti-b-actin, anti-FLAG and anti-cyclinA1 (SigmaAldrich); anti-BCL-2(C2), anti-NFkBp50, anti-NFkBp65, anti-STAT3 (Santa Cruz Biotechnology, CA, USA); anti-CREB, anti-PhosphoCREB, anti-FOS, anti-CIP1-p21, anti-PhosphoSGK (Upstate Biotechnology). HL60 treated with MG132 as proteasome inhibitor (10 mM) or with staurosporin as protein kinase C inhibitor and consequently of mitogen-activated protein kinases (MAPKs) (1 nM) were probed with anti-Phospho-extracellular signal-regulated protein kinase (ERK)-1/2 (Thr202/Tyr204) (Cell Signaling Technology, Danvers, MA, USA) and anti-CREM1 (Santa Cruz Biotechnology). The specific bands of target proteins were visualized by enhanced chemoluminescence (ECL advance) according to the manufacturer's instructions (GE-Healthcare), and the density of bands was quantified using the ScionImage software.
Immunoprecipitation
Cells were treated with preoteasome inhibitor MG132 (10 mM) for 4 h to have the higher ICER concentration. Then, cells were lysed in 200 ml of ice-cold 1 Â CHAPSO lysis buffer (137 mM KCl; 5 mM MgCl 2 ; 1 mM EDTA; 1 mM EGTA; 20 mM Tris-HCl) containing protease and phosphatase inhibitor cocktail (Sigma). A quantity of 500 mg of protein extracts were precleared with 30 ml of Protein A-Sepharose (Sigma) immunoprecipitated with 2 mg of antibody anti-CREM1 (Santa Cruz Biotechnology) and 30 ml of protein A-sepharose. Immunoprecipitates were washed three times with 200 ml of ice-cold 1 Â CHAPSO lysis buffer and eluted with Laemlii buffer for 10 min at 100 1C and subjected to SDS-polyacrylamide gel electrophoresis. Proteins were transferred onto polyvinylidene difluoride membranes and analyzed by immunoblotting with anti-Phospho-ERK1/2 (Cell Signaling Technology) and anti-CREM1 (Santa Cruz Biotechnology) followed by Protein A horseradish peroxidase (Sigma) and detected by enhanced chemoluminescence reagent (GE-Healthcare).
Data analysis
Values were presented as mean ± s.d. Significance between experimental values was determined by Student's unpaired t-test and one-way ANOVA was used to test differences in repeated measures across experiments. Po0.05 was considered significant.
Results
ICER decreases CREB expression in HeLa and HL60
Previous findings from our laboratory have shown that CREB protein was overexpressed in patients at diagnosis of leukemia, whereas ICER mRNA was downregulated. In this study, we analyze CREB and ICER protein expression in HeLa as a good model for transfection experiments, and a variety of leukemic cell lines. We also included two healthy BM after sorting of CD34 þ and CD34À subpopulation cells in the study. Results demonstrated that CREB protein levels were high in HeLa and in all leukemia cell lines (Figure 1 ), but undetectable in sorted normal hematopoietic stem cells. On the contrary, ICER was not detected in any of the analyzed cell lines, but was expressed in normal hematopoietic cells (CD34À), supporting the association of CREB expression with leukemic tissue 19 and ICER with healthy tissue. The stable expression of ICER (HL60 þ ICER in Figure 1a ), as well as the transient transfection of ICER (t ICER in Figure 1b ) in HeLa and HL60 induced the reduction of the active phosphorylated form of CREB (P-CREB) compared with transfected controls (t EV).
ICER controls HL60 colony formation in vitro and blasts dissemination in vivo
To understand if ICER-induced CREB downregulation could be implicated in leukemia, in vitro clonogenicity assay was performed. On day 12, after plating HL60 þ ICER-formed colonies were found to be significantly lower in number (Table 1 ; n ¼ 3, Po0.05), as well as more diffuse and smaller compared with HL60 þ EV colonies formed (control cell line). To establish if ICER has a function as tumor suppressor in leukemia, as it has been recently found in other solid tumors, in vivo experiments were performed. Nonobese diabetic-severe combined immunodeficient mice were inoculated with HL60 þ ICER and with HL60 þ EV cells. At the time of killing, the weight of HL60 þ ICER-inoculated mice was significantly higher (22.25 ± 0.85 g) than the EV-inoculated mice (19.75±0.25 g, P ¼ 0.031). BM engraftment and invasion of extramedullary sites were evaluated. Results revealed that HL60 þ ICER and HL60 þ EV cells similarly engrafted the BM (Table 1) , but HL60 þ ICER cells significantly reduced PB invasion (P ¼ 0.04), as well as spleen invasion (P ¼ 0.03). BM slides were also evaluated for vascular morphometric parameters. HL60 þ ICER-inoculated mice showed significant differences in microvessel numbers (P ¼ 0.036) and total In vitro experiments showed a significant lower colonies formation number. In vivo cell lines were both injected in nonobese diabetic-severe combined immunodeficient mice. Five mice per group were killed 3 weeks after injection and tumorigenity was analyzed. The engraftment was quantified by flow cytometry analyzing the positivity to the CD45 human ratio antigen (hCD45 + ) versus the murine CD45 + cells in BM and PB. Results are expressed as means ± s.e.m. The presence of leukemia cells or normal hematopoiesis was evaluated in slides by immunohistochemistry using anti hMHCI (H-300, Santa Cruz) antibodies in BM and spleen tissues, fixed, paraffined and sectioned at 6 mm onto charged slides. Blast invasion was measured by considering positive area in mm 2 in comparison with the normal hematopoietic area, which was negative for the staining. BM angiogenesis was determined by the use of anti-CD34 antibodies. Vascular morphometric parameters were quantified following the procedure by Pillozzi et al. 13 with the Leica DC Viewer Software. Results were analyzed independently by two investigators in slides at the magnitude of 40 Â. Student's t-test was used for P-values reported in the vascular area (P ¼ 0.008) compared with HL60 þ EV-inoculated mice, giving to ICER the capability to reduce BM angiogenesis in HL60.
ICER recognizes CRE elements when expressed in HL60
The inducible cyclic AMP (cAMP) early repressor is the endogenous repressor of CREB silencing promoter genes. Because ICER is not expressed in cell lines, the balance between activation and repression of CRE target genes in leukemia has never been described yet. We considered that the exogenous expression of ICER in our model, both in transient and stable transfected cells, could modify gene expression. To validate this hypothesis, a gene reporter assay was performed. A vector with a reporter gene (LUC) driven by the 4XCREs sequences in the promoter was used. ICER transiently transfected HeLa and HL60 cells which were used, and the LUC activity was measured.
Results showed that reporter activity significantly decreased when ICER (transient ICER expression, t ICER in the figure) was transiently expressed compared with control (transient EV expression, t EV) ( Figure 2 ). In particular, after 24 h of ICER transfection (white bars in the figure), LUC activity was decreased from 12.5 (t EV) to 1. 
ICER represses CREB-dependent gene expression
To test if ICER exogenous expression modifies CREB-dependent gene expression, a low-density array was designed. 96 CREB target genes were preferentially chosen. 20 We Table 2S ) HL60 þ EV cell line was used as calibrator and RQ of gene expression was considered ¼ 1 for each gene detected.
In HL60 þ ICER cell line, gene expression was downregulated if RQo1 with respect to the calibrator, whereas gene expression was upregulated if RQ41 in HL60 þ ICER cell line compared with calibrator). Among those genes, 40 genes (50%) were significantly downregulated or upregulated by more than twofold (RQp0.5 or RQX2.0, Po0.05; Table 2 ); 18 of these 40 genes were also significantly downregulated in stable HL60 þ ICER cell line (highlighted in Table 2 ). Gene ontology analysis, by KEGG database (http://www.genome.jp/kegg/tool/), 21 allowed us to identify significant genes inherent to the cell cycle-apoptosis pathway (ATM,CDKN1A (p21),CDKN1B (p27), CDKN2B (p15),and RB1); to MAPK signaling pathway (FOS, NR4A1, JUN, NFKB2, DUSP1 and DUSP4) and to acute myeloid leukemia pathway (PPARD, STAT3, PBK, RELB, TP53BP1). Considering that angiogenesis was documented to have been decreased in mice inoculated with HL60 þ ICER cell line, we analyzed HIF1a and VEGF genes, which play an important function in angiogenesis and which have CRE sequences in their promoters. Gene expression on HIF1a and VEGF mRNAs revealed that HIF1a expression was reduced by 30% in HL60 þ ICER cell line with respect to the HL60 þ EV cell line, as well as VEGF expression that was reduced by 56% (data not shown).
ICER defines a series of relevant CREB target genes in leukemia
To verify the binding of ICER to CRE sequences at gene promoters, experiments were performed in HL60 þ ICER and HL60 þ EV cell lines. Eight genes were chosen for immunoprecipitating chromatin at their promoters. P-CREB was used in stable HL60 þ EV cell line, and both P-CREB and anti-FLAG_ICER antibodies in HL60 þ ICER cell line. DNA pulled down was amplified by PCR and results demonstrated that all promoters were recognized and activated by CREB in HL60 þ EV (Figure 3a) . In HL60 þ ICER cell line, the immunoprecipitation with P-CREB and ICER revealed that ICER, when stably expressed, affects P-CREB binding to CREs. To better quantify the ability of ICER to destabilize CREB binding on promoters, we performed real-time quantification of DNA immunoprecipitated by P-CREB in HL60 þ EV and in HL60 þ ICER cell lines. In particular, the amount of DNA immunoprecipitated by CREB was significantly decreased for BCL-2 (P ¼ 0.001), p21 (P ¼ 0.030) and FOS (P ¼ 0.001) (Figure 3a at the right), as well as for STAT3, SGK, NFkBp50/ p65 in HL60 þ ICER compared with HL60 þ EV cell line, confirming that ICER counteracted CREB on same promoter genes, and that the disruption of gene expression discussed above depended on ICER expression. The fact that promoters ICER expression controls leukemia M Pigazzi et al bound both P-CREB and ICER factors could be explained by the fact that ICER decreased CREB expression, but did not nullify it. In this way, CREB and ICER can heterodimerize, exerting a repressive activity, similar to that of ICER/ICER homodimer. To evaluate if the downregulation of the mRNA could also correlate with a reduction of protein level, WB analyses after 48 h of transient and stable ICER expression were performed. Results revealed that exogenous expression of ICER affected mRNA expression and consequently protein levels. In particular, less protein abundance was observed for SGK, NFkBp65, FOS and STAT3 (Figure 3b , Po0.05 after densitometric analyses) in transiently transfected HL60 þ ICER compared with HL60 þ EVtransfected cells. A general downregulation of these proteins in ICER stable clones was also observed (data not shown).
ICER interacts with ERK and leads it to proteasome degradation
We supposed that ICER-lowered expression could be a result of its degradation. We used the proteasome inhibitor to evaluate if ICER was degraded in a proteasome-dependent manner. Results revealed that ICER protein increased during MG132 treatment (Figure 4a ). The fact that its degradation has been linked to the inhibition of MAPK kinases forced us to use staurosporin that inhibits protein kinase C and consequently the MAPK-dependent pathway. We found that whereas ERK1-2 expression was delayed, ICER expression was increased during treatment (Figure 4b ). This link between ICER and ERK was confirmed by coimmunoprecipitation experiment indicating that ICER might be driven to the proteasome by ERK1/2 in HL60 (Figure 4c ), suggesting that it could be a reason for ICERlowered expression in leukemia blasts.
Discussion and conclusion
Transcription factors have been described as being the major protein class whose alterations influence cell proliferation, differentiation and survival 22, 23 and their inappropriate activation has been demonstrated to have an important function in Table 2 Genes significantly modulated by ICER in HL60 acute leukemia. 24, 25 Therapies currently adopted in preclinical trials take advantage of those molecules and results encourage their knowledge to be improved in the future. 26, 27 In this research, we present data about two transcription factors that represent prospective targets of therapy in human disorders. We describe that exogenous ICER expression in HL60 cells, normally unexpressed in this cell line, potentiality repressed leukemia in vitro and in vivo. The function of ICER as a tumor suppressor in acute leukemia is described for the first time. ICER is demonstrated to influence transcriptional activity and turns out to be a crucial controller of the cAMP-dependent pathway activated by CREB in this system. Its lowered expression in leukemia might be considered the result of selective proteasome degradation through ERK1/2. We support the idea that ICER downregulation found in leukemia tissue must be considered to be a pathogenetic feature.
The evidence that ICER acts as a tumor suppressor gene in leukemia cell line HL60, as reported previously for other solid tumors, [28] [29] [30] first comes from the decreased clonogenicity ability of HL60 þ ICER cells in vitro. We used immunodeficent mice to confirm these data and reveal that HL60 þ ICER-injected mice have a mild leukemia phenotype for the reduced dissemination of tumor in extramedullary sites. Results confirm that ICER is an important factor to be elucidated in leukemia process. We considered blast dissemination to be a fundamental step in disease progression. The observed reduced BM angiogenesis induced by HL60 þ ICER cells suggested the possibility that ICER had a function in this phenomenon. Vascularization of neoplastic tissue is, in fact, a complicated balance of angiostatic and angiogenic factors that come from different signaling pathways, including cAMP/CREB. 31 Our results show that ICER represses the expression of the major involvement of two genes in angiogenesis, HIF1a and VEGF. Moreover, ICER caused a reduction of Jak3 and Stat3 expression as well as of the final effector IL6. 32, 33 The disruption of the VEGF signaling pathway, along with the deregulation of many other genes (ATM, NFkB, RelB) 34 explain how ICER might be able to control cell activities contrasting leukemia through gene regulation.
The restoration of ICER expression in HL60 establishes its ability to modulate CREB transactivation potential, confirming results found in other models. [35] [36] [37] We document that ICER represses CRE at specific gene promoters, giving CREB and ICER expression a direct function in determining leukemic or healthy gene expression. The characterization of genes heavily influenced by ICER exogenous expression points toward novel targets that could improve the understanding of the molecular pathways involved in the leukemogenic process. Genes related to cell cycle and apoptosis pathways such as ATM, CDKN1A, CDKN1B, CDKN2B and RB1 were severely compromised, as well as genes involved in acute leukemia pathway such as PPARD, STAT3, PBK, RELB and TP53BP1 already known to influence tumor susceptibility. [38] [39] [40] In particular, STAT3 is persistently activated in many human cancers and enhances transformation or blocks apoptosis in cell cultures. TP53BP1 is a key transducer of the DNA damage checkpoint signal; PBK has recently been demonstrated to be involved in leukemic growth arrest. 41 CREB and ICER expression might be considered useful to monitor leukemia activity. 42 The possibility to manipulate CREB and ICER reciprocal expression, influencing the regulation of the transcription of their target genes, could potentially establish innovative therapeutic opportunities. 43 Furthermore, the downregulation of genes of the MAPK signaling pathway (FOS, NR4A1, JUN, NFKB2, DUSP1, DUSP4) might be used to elucidate ICER involvement in chemotherapy response and cell death. [44] [45] [46] Finally, we investigate the mechanism of ICER downregulation. Because ICER activity is mainly determined by its intracellular concentration rather than post-translational modification, we focused on the protein degradation mechanisms. 47 Results indicate that ICER immunoprecipitates with ERK1/2 in HL60 and that this complex migrates to the proteasome. This might be considered to be a possible mechanism that could explain CREB overexpression in leukemia. Therefore, we assume that the rapid degradation of ICER blocks its ability to control gene expression triggering to leukemia phenotype. Moreover, ICER-lowered expression prevents CREB/ICER heterodimerization, which would lead CREB protein to degrade. 48, 49 Future studies will implement this mechanism to influence CREB/ICER expression in tumor. 50 The newly discovered function of ICER in mediating leukemia gives new insight into future treatment strategies for clinical implementation. Therefore, further investigation into the CREB/ ICER connection could improve our knowledge of this new molecular pathway involved in acute leukemia development. 
